Application note: Determining the structure of impurities
Posted: 21 November 2019 | SGS Life Sciences | No comments yet
Most, if not all pharmaceutical companies will have experienced a product, that has been on the market for a long time, to suddenly and unexpectedly trigger a signal for an unknown substance in the quality control (QC) laboratory approval process.
Deciding on the next course of action is of the upmost importance to the company’s success. Ultimately, the most important consideration is product quality and safety, however the financial impact is also a commercial priority too.
Related content from this organisation
- Press Release: Overcoming contamination risks during biologicals production: Mycoplasma & virus testing
- Webinar: Overcoming contamination risks during biologicals production: Mycoplasma & virus testing
- SGS joins forces with Agilex Biolabs
- SGS ISL marks two-year anniversary
- Whitepaper: Changing regulatory environment for nitrosamine impurities